DR info

臨床試験数 : 76 / 薬物数 : 98 - (DrugBank : 31) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 65

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Alpha-tocotrienolquinone
   PTC Therapeutics, Inc.
      2021   Phase 2;Phase 3   EUCTR2020-002812-36-FR   Australia;Brazil;Canada;France;Germany;Italy;New Zealand;Spain;United States;
      2021   Phase 2;Phase 3   EUCTR2020-002812-36-ES   Australia;Brazil;Canada;France;Germany;Italy;Spain;United States;
      2021   Phase 2;Phase 3   EUCTR2020-002812-36-DE   Australia;Brazil;Canada;France;Germany;Italy;New Zealand;Spain;United States;
Artesunate
   INSERM
      2021   Phase 1;Phase 2   EUCTR2021-000171-36-FR   France;
Artesunate Oral Product
   Institut National de la Santé Et de la Recherche Médicale, France
      2021   Phase 1/Phase 2   NCT04921930   -
BINOCRIT*1SIR 40000UI/1ML
   UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II
      2012   Phase 2   EUCTR2011-006156-37-IT   Italy;
Baclofen
   DAIICHI SANKYO COMPANY, LIMITED
      -   Phase 4   JPRN-JapicCTI-050031   -
Bupropion & Citalopram
   University of Colorado, Denver
      2012   Phase 4   NCT01716221   -
Butylphthalide
   Xiangya Hospital of Central South University
      2017   Phase 2 study   ChiCTR-IIR-17012717   China;
C-Trelin OD Tab(5mg Taltirelin Hydrate)
   MediForum Pharm
      2019   Phase 4   NCT04107740   Korea, Republic of;
CTI-1601
   Larimar Therapeutics, Inc.
      2020   Phase 1   NCT04519567   United States;
      2019   Phase 1   NCT04176991   United States;
Cabaletta for IV infusion once weekly during 24 weeks
   Bioblast Pharma Ltd.
      2014   Phase 2   NCT02147886   Israel;
Calcitriol
   Berta Alemany
      2021   Phase 4   NCT04801303   Spain;
Coenzyme Q10
   Department of Neurology, Tokushima University, Japan
      2018   -   JPRN-UMIN000031788   Japan;
DT-216
   Design Therapeutics
      2022   Phase 1   NCT05285540   United States;
Deferiprone
   APOPHARMA INC., TORONTO, ONTARIO
      2009   -   EUCTR2009-010865-22-IT   Belgium;France;Italy;Spain;
      2008   -   EUCTR2007-003331-23-IT   Belgium;France;Italy;Spain;United Kingdom;
EGB 761 (r)
   BEAUFOUR IPSEN PHARMA
      2008   -   EUCTR2007-005371-34-FR   France;
EGb 761
   Ipsen
      2008   Phase 2   NCT00824512   France;
EPREX*1FL 40000UI/ML 1ML
   ISTITUTO NEUROLOGICO CARLO BESTA
      2007   -   EUCTR2007-003357-85-IT   Italy;
EPREX*1SIR 10000UI 1ML
   UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II
      2012   Phase 2   EUCTR2011-006156-37-IT   Italy;
EPREX*1SIR 40000UI/ML 1ML
   UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II
      2012   Phase 2   EUCTR2011-006156-37-IT   Italy;
EU1/97/031-032
   Medizinische Universität Innsbruck, Univ.-Klinik für Neurologie
      2009   Phase 2   EUCTR2008-000040-13-AT   Austria;
EU1/97/031/031-032
   Dr. Sylvia Boesch
      2006   Phase 2   EUCTR2005-005938-12-AT   Austria;
Epoeitin beta
   Medizinische Universität Innsbruck, Univ.-Klinik für Neurologie
      2009   Phase 2   EUCTR2008-000040-13-AT   Austria;
Epoetin alfa
   Federico II University
      2013   Phase 2   NCT01493973   Italy;
Erythropoietin
   ISTITUTO NEUROLOGICO CARLO BESTA
      2007   -   EUCTR2007-003357-85-IT   Italy;
Etravirine Tablets
   IRCCS Eugenio Medea
      2020   Phase 2   NCT04273165   Italy;
Flumazenil
   Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
      2013   -   JPRN-UMIN000011111   Japan;
Gamma interferon
   Azienda Policlinico Umberto I
      2013   Phase 2   NCT02035020   Italy;
   IRCCS Eugenio Medea
      2016   Phase 2   NCT03888664   -
Glentek 50 mg compresse rivestite con film
   DIPARTIMENTO DI NEUROSCIENZE SALUTE MENTALE E ORGANI DI SENSO - NESMOS - SAPIENZA UNIVERSITÀ DI ROMA
      2020   Phase 2   EUCTR2018-000282-37-IT   Italy;United States;
Glentek 50 mg film-coated tablets
   DIPARTIMENTO DI NEUROSCIENZE SALUTE MENTALE E ORGANI DI SENSO - NESMOS - SAPIENZA UNIVERSITÀ DI ROMA
      2020   Phase 2   EUCTR2018-000282-37-IT   Italy;United States;
Granocyte
   University of Bristol
      2018   Phase 2   EUCTR2017-003084-34-GB   United Kingdom;
H-116PI-DE.pdf
   Medizinische Universität Innsbruck, Univ.-Klinik für Neurologie
      2009   Phase 2   EUCTR2008-000040-13-AT   Austria;
High-dose intravenous immunoglobulin (IVIG)
   National Institute of Neurological Disorders and Stroke (NINDS)
      2002   Phase 2   NCT00034242   United States;
IMUKIN - 6 FLACONI 0.5 ML 100 MCG
   ASSOCIAZIONE LA NOSTRA FAMIGLIA - SEZIONE SCIENTIFICA I.R.C.C.S. E.MEDEA
      2016   Phase 2   EUCTR2015-002432-40-IT   Italy;
IMUKIN*SC 6F 0,5ML 100MCG
   AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
      2013   -   EUCTR2012-001881-14-IT   Italy;
INTELENCE - 200 MG - COMPRESSA -USO ORALE - FLACONE (HDPE) 60 COMPRESSE
   ASSOCIAZIONE LA NOSTRA FAMIGLIA - SEZIONE SCIENTIFICA I.R.C.C.S. E.MEDEA
      2020   Phase 2   EUCTR2019-002618-38-IT   Italy;
Idebenone
   National Institute of Neurological Disorders and Stroke (NINDS)
      2005   Phase 2   NCT00229632   United States;
      2004   Phase 1   NCT00078481   United States;
      2001   Phase 1   NCT00015808   United States;
Iron chelating intervention
   Assistance Publique - Hôpitaux de Paris
      2005   Phase 1/Phase 2   NCT00224640   France;
J05AG04
   ASSOCIAZIONE LA NOSTRA FAMIGLIA - SEZIONE SCIENTIFICA I.R.C.C.S. E.MEDEA
      2020   Phase 2   EUCTR2019-002618-38-IT   Italy;
KPS-0373
   Kissei Pharmaceutical Co., Ltd.
      2016   Phase 3   NCT02889302   Japan;
      2011   Phase 2   NCT01384435   Japan;
      2009   Phase 2   NCT01004016   Japan;
      2004   Phase 2   NCT00863538   Japan;
KPS-0373, High dose
   Kissei Pharmaceutical Co., Ltd.
      2013   Phase 3   NCT01970137   Japan;
      2013   Phase 3   NCT01970124   Japan;
      2013   Phase 3   NCT01970111   Japan;
      2013   Phase 3   NCT01970098   Japan;
KPS-0373, Low dose
   Kissei Pharmaceutical Co., Ltd.
      2013   Phase 3   NCT01970137   Japan;
      2013   Phase 3   NCT01970124   Japan;
      2013   Phase 3   NCT01970111   Japan;
      2013   Phase 3   NCT01970098   Japan;
Lenograstim
   University of Bristol
      2018   Phase 2   EUCTR2017-003084-34-GB   United Kingdom;
Lu AA24493
   H. Lundbeck A/S
      2009   -   EUCTR2008-003662-25-AT   Austria;Germany;Italy;
      -   -   EUCTR2008-003662-25-DE   Austria;Germany;Italy;
   H.Lundbeck A/S
      2009   -   EUCTR2008-003662-25-IT   Austria;Germany;Italy;
MIB-626
   Metro International Biotech, LLC
      2021   Phase 2   NCT04817111   United States;
MIN-102
   Minoryx Therapeutics, S.L.
      2019   Phase 2   NCT03917225   Belgium;France;Germany;Spain;
Methylprednisolone
   Children's Hospital of Philadelphia
      2015   Early Phase 1   NCT02424435   United States;
Neo-Recormon
   Dr. Sylvia Boesch
      2006   Phase 2   EUCTR2005-005938-12-AT   Austria;
Neorecormon
   Medizinische Universität Innsbruck, Univ.-Klinik für Neurologie
      2009   Phase 2   EUCTR2008-000040-13-AT   Austria;
Nicotinamide
   RWTH Aachen University
      2022   Phase 2   NCT03761511   Austria;France;Germany;Italy;Spain;United Kingdom;
   RWTH Aachen University, Center for Translational & Clinical Research Aachen (CTC-A)
      2020   Phase 2;Phase 3   EUCTR2017-002163-17-GB   Austria;Germany;Spain;United Kingdom;
Omaveloxolone Capsules,
   Reata Pharmaceuticals, Inc.
      2015   Phase 2   NCT02255435   Australia;Austria;Brazil;Italy;United Kingdom;United States;
PTC743
   PTC THERAPEUTICS INC.
      2021   Phase 2;Phase 3   EUCTR2020-002812-36-IT   Australia;Brazil;Canada;France;Germany;Italy;Spain;United States;
   PTC Therapeutics, Inc.
      2021   Phase 2;Phase 3   EUCTR2020-002812-36-FR   Australia;Brazil;Canada;France;Germany;Italy;New Zealand;Spain;United States;
      2021   Phase 2;Phase 3   EUCTR2020-002812-36-ES   Australia;Brazil;Canada;France;Germany;Italy;Spain;United States;
      2021   Phase 2;Phase 3   EUCTR2020-002812-36-DE   Australia;Brazil;Canada;France;Germany;Italy;New Zealand;Spain;United States;
RHuG-CSF
   University of Bristol
      2018   Phase 2   EUCTR2017-003084-34-GB   United Kingdom;
Resveratrol
   Murdoch Childrens Research Institute
      2019   Phase 2   NCT03933163   Australia;
      2011   Phase 1/Phase 2   NCT01339884   Australia;
Riluzole
   S. Andrea Hospital
      2019   Phase 2/Phase 3   NCT03660917   Italy;
Riluzole PMCS
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2017   Phase 3   EUCTR2017-001481-23-FR   France;
Riluzolo
   DIPARTIMENTO DI NEUROSCIENZE SALUTE MENTALE E ORGANI DI SENSO - NESMOS - SAPIENZA UNIVERSITÀ DI ROMA
      2020   Phase 2   EUCTR2018-000282-37-IT   Italy;United States;
Rokan (r) Novo
   BEAUFOUR IPSEN PHARMA
      2008   -   EUCTR2007-005371-34-FR   France;
Rosuvastatin
   Children's Hospital of Philadelphia
      2016   Early Phase 1   NCT02705547   United States;
SUB09246MIG
   RWTH Aachen University, Center for Translational & Clinical Research Aachen (CTC-A)
      2020   Phase 2;Phase 3   EUCTR2017-002163-17-GB   Austria;Germany;Spain;United Kingdom;
Standardized Ginkgo Biloba Extract (EGb 761 (r)
   BEAUFOUR IPSEN PHARMA
      2008   -   EUCTR2007-005371-34-FR   France;
TAK-831
   Neurocrine Biosciences
      2017   Phase 2   NCT03214588   United States;
Varenicline
   Niigata University
      2013   Phase 1,2   JPRN-UMIN000011560   Japan;
Vatiquinone
   PTC THERAPEUTICS INC.
      2021   Phase 2;Phase 3   EUCTR2020-002812-36-IT   Australia;Brazil;Canada;France;Germany;Italy;Spain;United States;
   PTC Therapeutics
      2020   Phase 2/Phase 3   NCT04577352   Australia;Brazil;Canada;France;Germany;Italy;New Zealand;Spain;United States;